Cryptococcal meningitis.
Conditions
Interventions
Sixty-three patients (over 18 years) will be included in this study, to be divided into three groups of 21, with confirmed clinical and laboratory diagnosis of neurocriptococcosis in HEM, between 2019
Drug
D02.886.675.933.250
E05.290.875
Sponsors
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Universidade Federal de Minas Gerais
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Older than 18 years. Cryptococcal meningitis.
Exclusion criteria
Exclusion criteria: Under 18 years. Pregnancy. Diabettes mellitus. Active liver failure. Bladder tumor. Recurrence of cryptococcosis. Prior antifungal therapy. Hypoglycemia. Congestive heart failure. Hypersensitivity to pioglitazone. Sertraline. Amiodarone Atorvastatin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality reduction in cryptococcosis patients to 10% (this figure is based on survival of mice in a preclinical trial in which IOP was associated with antifungal). | — |
Secondary
| Measure | Time frame |
|---|---|
| As secondary outcomes, it is expected: (i) Reduction of CSF fungal burden at the beginning of treatment; (ii) Negative CSF culture after 14 days; (iii) Lower occurrence of immune response reconstitution syndrome; (iv) Reduction of relapse occurrence; (v) Reduction of serious adverse effects; (vi) Reduction of levels of inflammatory mediators in blood and cerebrospinal fluid. | — |
Countries
Brazil
Contacts
Public ContactDaniel;Lívia Santos;Melo
Universidade Federal de Minas Gerais;Hospital Eduardo de Menezes - Rede FHEMIG
Outcome results
None listed